Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 771

The DOI matches its Crossref record; 298 of the 298 references it cites were found in a registry or an index.

TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants – past, present and future

Open access
Sedger, Lisa M., McDermott, Michael F. · 2014 · Cytokine & Growth Factor Reviews

Abstract

Tumor Necrosis Factor (TNF), initially known for its tumor cytotoxicity, is a potent mediator of inflammation, as well as many normal physiological functions in homeostasis and health, and anti-microbial immunity. It also appears to have a central role in neurobiology, although this area of TNF biology is only recently emerging. Here, we review the basic biology of TNF and its normal effector functions, and discuss the advantages and disadvantages of therapeutic neutralization of TNF - now a commonplace practice in the treatment of a wide range of human inflammatory diseases. With over ten years of experience, and an emerging range of anti-TNF biologics now available, we also review their modes of action, which appear to be far more complex than had originally been anticipated. Finally, we highlight the current challenges for therapeutic intervention of TNF: (i) to discover and produce orally delivered small molecule TNF-inhibitors, (ii) to specifically target selected TNF producing cells or individual (diseased) tissue targets, and (iii) to pre-identify anti-TNF treatment responders. Although the future looks bright, the therapeutic modulation of TNF now moves into the era of personalized medicine with society's challenging expectations of durable treatment success and of achieving long-term disease remission.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cytogfr.2014.07.016

Cites

298 of 298 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 201–298 of 298

Research works printed but not linked: 65

  1. Matthews, 1980, Tumour-necrosis factor from the rabbit. IV. Purification and chemical characterization, Br J Cancer, 42, 416, 10.1038/bjc.1980.253 · doi:10.1038/bjc.1980.253
  2. Matthews, 1979, Tumour-necrosis factor from the rabbit. III. Relationship to interferons, Br J Cancer, 40, 534, 10.1038/bjc.1979.218 · doi:10.1038/bjc.1979.218
  3. Prince, 1982, Inhibition of L-cell growth in agarose (ILGA): a simple inexpensive method for the detection and quantitation of factors inhibiting tumor cell growth, J Immunol Methods, 48, 367, 10.1016/0022-1759(82)90337-4 · doi:10.1016/0022-1759(82)90337-4
  4. Bloksma, 1983, Antitumour activity of endotoxin, concanavalin A and poly I: C and their ability to elicit tumour necrosis factor, cytostatic factors, and interferon in vivo, Cancer Immunol Immunother, 16, 35, 10.1007/BF00199903 · doi:10.1007/bf00199903
  5. English, 1991, Differential regulation of lymphotoxin and tumor necrosis factor genes in human T lymphocytes, J Biol Chem, 266, 7108, 10.1016/S0021-9258(20)89617-3 · doi:10.1016/s0021-9258(20)89617-3
  6. Turner, 1988, Comparison of patterns of expression of tumour necrosis factor, lymphotoxin and interleukin-6 mRNA, Biochem Biophys Res Commun, 153, 1144, 10.1016/S0006-291X(88)81347-0 · doi:10.1016/s0006-291x(88)81347-0
  7. Ziegler-Heitbrock, 1986, Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity, Cancer Res, 46, 5947
  8. Haranaka, 1987, Antitumour effects of tumour necrosis factor: cytotoxic or necrotizing activity and its mechanism, Ciba Found Symp, 131, 140
  9. Schwartz, 1989, A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy, Biotherapy, 1, 207, 10.1007/BF02170889 · doi:10.1007/bf02170889
  10. Zamkoff, 1989, A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy, J Biol Response Mod, 8, 539
  11. Negrier, 1991, Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer, J Immunother, 11, 93, 10.1097/00002371-199202000-00003 · doi:10.1097/00002371-199202000-00003
  12. Xin, 2006, Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNF-alpha-mediated ‘reverse signaling’, Int J Mol Med, 18, 885
  13. Austgulen, 1986, Role of monocyte cytotoxic factor in cytolysis of actinomycin D-treated WEHI 164 cells mediated by freshly isolated human adherent mononuclear blood cells, Cancer Res, 46, 4566
  14. Munker, 1987, In vitro action of tumor necrosis factor on myeloid leukemia cells, Blood, 69, 1102, 10.1182/blood.V69.4.1102.1102 · doi:10.1182/blood.v69.4.1102.1102
  15. Suyama, 1985, Effects of murine tumor necrosis factor on friend erythroleukemic cells, Exp Cell Biol, 53, 85
  16. Sedger, 2005, Viral inhibition of tumour necrosis factor-α and TNFα and TNF-receptor induced apoptosis and inflammation, Curr Med Chem Anti Inflam Anti Aller, 4, 597, 10.2174/156801405774933124 · doi:10.2174/156801405774933124
  17. Warzocha, 1995, Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system, Eur Cytokine Netw, 6, 83
  18. Fiers, 1987, Structure-function relationship of tumour necrosis factor and its mechanism of action, Ciba Found Symp, 131, 109
  19. Boecke, 2012, Factor associated with neutral sphingomyelinase activity mediates navigational capacity of leukocytes responding to wounds and infection: live imaging studies in zebrafish larvae, J Immunol, 189, 1559, 10.4049/jimmunol.1102207 · DOI
  20. Christoforidis, 2003, Isolated limb perfusion: distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response, Arch Surg, 138, 17, 10.1001/archsurg.138.1.17 · doi:10.1001/archsurg.138.1.17
  21. Yousaf, 2005, Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-κB activation, Arthritis Rheum, 52, 2906, 10.1002/art.21268 · DOI
  22. Upton, 1991, Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence, Virology, 184, 370, 10.1016/0042-6822(91)90853-4 · doi:10.1016/0042-6822(91)90853-4
  23. Hutas, 2010, Golimumab as the first monthly subcutaneous fully human anti-TNF-α antibody in the treatment of inflammatory arthropathies, Immunotherapy, 2, 453, 10.2217/imt.10.34 · doi:10.2217/imt.10.34
  24. Meroni, 2014, Tumour necrosis factor-α antagonists in the treatment of Rheumatoid arthritis: an immunological perspective, BioDrugs, 28, S5, 10.1007/s40259-013-0063-0 · DOI
  25. Bendele, 1999, Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats, Clin Exp Rheumatol, 17, 553
  26. McComb, 1999, Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy, J Rheumatol, 26, 1347
  27. Trinchard-Lugan, 2001, Safety, pharmakinetics and pharmacodynamics of recombinant human tumour necrosis factor binding proteins-1 (Onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers, Eur Cytokine Netw, 12, 391
  28. Kay, 2013, Biosimilars to treat inflammatory arthritis: the challenge of proving identity, Ann Rheum Dis, 72, 1589, 10.1136/annrheumdis-2012-203198 · doi:10.1136/annrheumdis-2012-203198
  29. Scheinberg, 2012, The advent of biosimilar therapies in rheumatology-“O brave new world”, Nat Rev Rheumatol, 8, 430, 10.1038/nrrheum.2012.84 · doi:10.1038/nrrheum.2012.84
  30. Leck, 1962, Incidence of malformations since the introduction of thalidomide, Br Med J, 2, 16, 10.1136/bmj.2.5296.16 · doi:10.1136/bmj.2.5296.16
  31. Ringheanu, 2004, Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease, Inflamm Bowel Dis, 10, 801, 10.1097/00054725-200411000-00015 · doi:10.1097/00054725-200411000-00015
  32. Xin, 2006, Dual regulation of soluble tumour necrosis factor-α inducing activation of human monocytic cells via modulation transmembrane TNFα-metiated “reverse signalling”, Int J Mol Med, 18, 885
  33. Mitoma, 2005, Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-α, Gastroenterology, 128, 376, 10.1053/j.gastro.2004.11.060 · DOI · Paper page
  34. Nestorov, 2005, Clinical pharmacokinetics of TNF antagonists: how do they differ?, Semin Arthritis Rheum, 34, 12, 10.1016/j.semarthrit.2005.01.004 · doi:10.1016/j.semarthrit.2005.01.004
  35. Steenholdt, 2012, Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease, J Crohns Colitis, 6, 108, 10.1016/j.crohns.2011.08.001 · DOI
  36. Bracaglia, 2012, Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age, J Rheumatol, 39, 1287, 10.3899/jrheum.111555 · doi:10.3899/jrheum.111555
  37. Li Gobbi, 2005, Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab), J Clin Rheumatol, 11, 119, 10.1097/01.rhu.0000158527.20518.30 · doi:10.1097/01.rhu.0000158527.20518.30
  38. Mancini, 2007, Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-α (anti-TNF-alpha) treatment, Clin Microbiol Infect, 13, 1036, 10.1111/j.1469-0691.2007.01796.x · doi:10.1111/j.1469-0691.2007.01796.x
  39. Lanternier, 2013, Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study, Chest, 144, 990, 10.1378/chest.12-2820 · doi:10.1378/chest.12-2820
  40. Hofmann, 2009, Fulminant legionellosis in two patients treated with infliximab for Crohn's disease: case series and literature review, Can J Gastroenterol, 23, 829, 10.1155/2009/836938 · doi:10.1155/2009/836938
  41. Kang, 2007, Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis, Korean J Intern Med, 22, 63, 10.3904/kjim.2007.22.1.63 · doi:10.3904/kjim.2007.22.1.63
  42. Smith, 2002, Viral pneumonia as a serious complication of etanercept therapy, Ann Intern Med, 136, 174, 10.7326/0003-4819-136-2-200201150-00020 · doi:10.7326/0003-4819-136-2-200201150-00020
  43. Cantini, 2014, Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance, J Rheumatol Suppl, 91, 47, 10.3899/jrheum.140102 · doi:10.3899/jrheum.140102
  44. Navarra, 2014, Risk of tuberculosis with anti-tumour necrosis factor-α therapy: substantially higher number of patients at risk in Asia, Int J Rheum Dis, 17, 3, 10.1111/1756-185X.12188 · doi:10.1111/1756-185x.12188
  45. Glenn, 2012, Epstein–Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer, PLoS One, 7, e48788, 10.1371/journal.pone.0048788 · doi:10.1371/journal.pone.0048788
  46. Mohan, 2001, Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides, Arthritis Rheum, 44, 2862, 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W · doi:10.1002/1529-0131(200112)44:12<2862::aid-art474>3.0.co;2-w
  47. Tanno, 2006, New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients, Clin Rheumatol, 25, 929, 10.1007/s10067-005-0097-x · doi:10.1007/s10067-005-0097-x
  48. Andreadou, 2013, Demyelinating disease following anti-TNFα treatment: a causal or coincidental association? Report of four cases and review of the literature, Case Rep Neurol Med, 2013, 671935
  49. Kaltsonoudis, 2014, Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study, Arthritis Res Ther, 16, R125, 10.1186/ar4582 · doi:10.1186/ar4582
  50. Ledingham, 2005, British thoracic society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-{alpha} treatments, Rheumatology (Oxford), 44, 1205, 10.1093/rheumatology/kei103 · doi:10.1093/rheumatology/kei103
  51. Lv, 2014, The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis, PLoS One, 9, e89422, 10.1371/journal.pone.0089442 · doi:10.1371/journal.pone.0089442
  52. Coulthard, 2013, Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients, Clin Exp Immunol, 170, 36, 10.1111/j.1365-2249.2012.04626.x · doi:10.1111/j.1365-2249.2012.04626.x
  53. Sandborn, 2013, A special meeting review edition: clinical research highlights in ibd: diagnosis and anti-tumor necrosis factor monitoring, Gastroenterol Hepatol, 9, 1
  54. Thomas, 2014, Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease, World J Gastroenterol, 20, 3609, 10.3748/wjg.v20.i13.3609 · doi:10.3748/wjg.v20.i13.3609
  55. Coulthard, 2011, Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients, Ann Rheum Dis, 70, 98, 10.1136/ard.2010.133249 · doi:10.1136/ard.2010.133249
  56. Sedger, 2006, Poxviral tumour necrosis factor receptor (TNFR)-like T2 proteins contain a concerved pre-ligand association domain (PLAD) that inhibits cellular TNFR2 induced cell death, J Virol, 80, 9300, 10.1128/JVI.02449-05 · DOI
  57. Macen, 1996, Expression of the myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes, Virology, 218, 232, 10.1006/viro.1996.0183 · doi:10.1006/viro.1996.0183
  58. Coulthard, 2012, Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients, Clin Exp Immunol, 170, 36, 10.1111/j.1365-2249.2012.04626.x · doi:10.1111/j.1365-2249.2012.04626.x
  59. Tobinick, 2010, Perispinal etanercept: a new therapeutic paradigm in neurology, Expert Rev Neurother, 10, 985, 10.1586/ern.10.52 · DOI
  60. Schabert, 2013, Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population, J Manag Care Pharm, 19, 621, 10.18553/jmcp.2013.19.8.621 · doi:10.18553/jmcp.2013.19.8.621
  61. Grover, 2012, Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health, J Law Med Ethics, 40, 234, 10.1111/j.1748-720X.2012.00661.x · doi:10.1111/j.1748-720x.2012.00661.x
  62. Deighton, 2010, BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy, Rheumatology (Oxford), 49, 1197, 10.1093/rheumatology/keq006a · doi:10.1093/rheumatology/keq006a
  63. Scott, 2009, NICE guidelines on anti-tumor necrosis factor therapy for RA, Nat Clin Pract Rheumatol, 5, 16, 10.1038/ncprheum0964 · doi:10.1038/ncprheum0964
  64. Nikas, 2003, Onercept. Serono., Curr Opin Investig Drugs, 4, 1369
  65. Davis, 2000, Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update, Ann Rheum Dis, 59, 41, 10.1136/ard.59.suppl_1.i41 · doi:10.1136/ard.59.suppl_1.i41

Cited by

See all 771

Metadata

Authors
Sedger, L. M., & McDermott, M. F.
Venue
Cytokine & Growth Factor Reviews
Publisher
Elsevier BV
Published
2014-08
Volume
25
Issue
4
Pages
453-472
ISSN
1359-6101 (ISSN-L)
OpenAlex
W1964249139
Cited by
771
References
298
FWCI
8.75
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.